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Abstract
The antiretroviral drug efavirenz displays many desirable pharmacokinetic properties such
as a long half-life enabling once daily dosing but suffers from central nervous system safety
issues. Various nanotechnologies have been explored to mitigate some of the limitations
with efavirenz. While there has been progress in increasing the bioavailability, there has
been no attempt to assess the impact of increased exposure to efavirenz on central ner-
vous system safety. The uptake of aqueous and solid drug nanoparticle (SDN) formulations
of efavirenz was assessed in the human cerebral microvessel endothelial cells/D3 brain
endothelial cell line. The mechanisms of uptake were probed using a panel of transport
and endocytosis inhibitors. The cellular accumulation of an efavirenz aqueous solution
was signiﬁcantly reduced by amantadine, but this was not observed with SDNs. The uptake
of efavirenz SDNs was reduced by dynasore, but concentrations of the efavirenz aqueous
solution were not affected. These data indicate that efavirenz is a substrate for trans-
porters in brain endothelial cells (amantadine is an inhibitor of organic cation transporters
1 and 2), and formation of SDNs may bypass this interaction in favour of a mechanism
involving dynamin-mediated endocytosis.
Introduction
The non-nucleoside reverse transcriptase inhibitor
efavirenz (EFV) has been used in ﬁrst-line human
immunodeﬁciency virus therapy for over 15 years (Rafﬁ
et al., 2014). Efavirenz displays potent activity against
wild-type human immunodeﬁciency virus-1, with an
© 2017 John Wiley & Sons Ltd
This is an open access article under the terms of the Creative Commons Attribution License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited.
2017 | Volume 2 | Issue 3 |
Page 157
Journal of Interdisciplinary Nanomedicine ISSN 2058-3273
IC50 of 0.51 ng/mL, inhibition constant (Ki) 2.93 nmol/L
and a long plasma half-life of 40–76 h, enabling once
daily dosing (Adkins and Noble, 1998; Best et al.,
2011). Despite these favourable properties, EFV has
very poor water solubility (<10 μg/mL) and bioavail-
ability can be poor resulting in highly variable plasma
exposure after oral administration (Siccardi et al.,
2015).
Recently, we reported an EFV solid drug nanoparticle
(SDN) formulation manufactured using an emulsion-
templated freeze-drying (ETFD) approach (McDonald
et al., 2014). Solid drug nanoparticles containing
70 wt% drug relative to polymer and surfactant excipi-
ents were successfully generated and displayed aug-
mented transcellular permeation across Caco-2 cells
with reduced cytotoxicity. Moreover, in vivo pharmaco-
kinetic studies performed in rats demonstrated an in-
crease in plasma EFV concentrations of approximately
fourfold following a single oral dose (McDonald et al.,
2014). Using SDNs, manufactured using ETFD, but com-
posed of ﬂuorescence resonance energy transfer dyes,
intact particles were demonstrated to traverse an
intact Caco-2 monolayer (McDonald et al., 2012).
If intact SDNs enter the systemic circulation after
oral administration, a differential passage across the
blood brain barrier (BBB) may be predicted.
Importantly, this may inﬂuence EFV-associated
neurocognitive adverse events such as depression, anx-
iety, and abnormal dreams (Sanchez Martin et al.,
2013), which are known to negatively impact treatment
(Leutscher et al., 2013).
One of the major obstacles to drug permeation into
the brain is the battery of transport proteins within
the brain endothelium (Al-Ghananeem et al., 2013;
Yilmaz et al., 2012). Many antiretrovirals are substrates
for one or more drug transporters, which limit or
completely extrude them from the brain (Ene et al.,
2011); however, the interaction of EFV with trans-
porters has not been thoroughly characterised.
Although there have been genetic associations be-
tween ABCB1 polymorphisms with EFV pharmacody-
namics (Fellay et al., 2002), in vitro evidence
indicates that EFV is not a substrate for P-gp (Janneh
et al., 2009; Leschziner et al., 2007). Some evidence in-
dicates that EFV may be a substrate for Breast Cancer
Resistance Protein (BCRP) (ATP-binding cassette sub-
family G member 2 (ABCG2)) and an ex vivo model
showed increased mucosal to serosal permeation of
EFV in everted gut sacs (Peroni et al., 2011). Efavirenz
may also be a substrate for one or more solute carrier
organic anion transporters, because its cellular accu-
mulation was reduced by montelukast and estrone-3-
sulphate (Janneh et al., 2009). However, convincing
data regarding substrate afﬁnity of EFV for active trans-
port systems have remained elusive.
Although the size of a nanoparticle may preclude in-
teractions with transport proteins, other methods of
cellular uptake may affect them. Endocytosis includes
multiple mechanisms such as clathrin-mediated
endocytosis, calveolae-mediated endocytosis, and
micropinocytosis that mammalian cells have developed
for the uptake of molecules from the extracellular envi-
ronment (Mukherjee et al., 1997). Macropinocytosis is
typically involved in uptake of larger particles
(<2 μM), whereas clathrin-mediated (<300 nm) and
caveolae-mediated (<80 nm) endocytosis may predom-
inate for smaller particles (Canton and Battaglia, 2012).
This study investigated differential uptake of EFV
SDNs relative to an aqueous solution in the human cere-
bral microvessel endothelial cells (hCMEC)/D3 cell line
in vitro, which is derived from human microvascular
brain endothelial cells (Alﬁrevic et al., 2015; Dickens
et al., 2012; Weksler et al., 2013). The hCMEC/D3 was
selected for its frequent application as an in vitro
model and characterisation as an immortalised BBB cell
line. The HCMEC/D3 cell line exhibits many of the char-
acteristics of the BBB, such as expression of protein
necessary for tight junction formation, polarised ex-
pression of multiple transporter proteins (including
P-gp, BCRP, and organic cation transporters) (Poller
et al., 2008; Sekhar et al., 2017), and endocytic pro-
cesses (Ilina et al., 2015). To investigate the putative
mechanisms, uptake was assessed in the presence and
absence of broad-spectrum transport (inﬂux and efﬂux)
and endocytosis inhibitors.
Methods
Materials
Pharmaceutical grade α-tocopherol polyethylene glycol
succinate (TPGS) was purchased from BASF (Royal
Tunbridge Wells, UK). Pharmaceutical grade polyvinyl
alcohol (PVA grade 4–88, MW 57–77,000) was purchased
from Merck KGaA (Darmstadt, Germany). Chloroform
(CHCl3) and dichloromethane (DCM) were purchased
from Fisher Scientiﬁc (Loughborough, UK). Efavirenz
was purchased from LGM Pharma (Chicago, USA) and
donated by CIPLA (Mumbai, India). Endothelial Growth
Basal Medium (EBM-2) media was purchased from Lonza
(Slough, UK), and penicillin-streptomycin, chemically
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deﬁned lipid concentrate, and HEPES were purchased
from Invitrogen (Paisley, UK). Fetal bovine serum gold
was purchased from PAA, the Cell Culture Company
(Cambridge, UK). The hCMEC/D3 cell line was a kind
gift from Pierre-Olivier Couraud (INSERM, Paris,
France). All other consumables were purchased from
Sigma Aldrich (Dorset, UK).
Manufacture and physical characterisation of
efavirenz solid drug nanoparticles
Preparation of emulsion-templated freeze-dried
monoliths containing 70% efavirenz
Stock solutions of EFV (70 mg/mL in CHCl3), PVA
(22.5 mg/mL in water), and TPGS (22.5 mg/mL in wa-
ter) were prepared. The three stock solutions were
added to a sample tube in the ratio 100:90:45 (l μL)
(EFV:PVA:TPGS) plus 265 μL water. The ﬁnal solid mass
ratio was therefore 70% EFV: 20% PVA: 10% TPGS (total
solid mass 10 mg) in a 1:4 CHCl3 to water mixture (total
volume 0.5 mL). The sample was emulsiﬁed using a
Covaris S2x acoustic homogenisation system for 30 sec
with a duty cycle of 20, an intensity of 10, and
500 cycles/burst in frequency sweeping mode. Immedi-
ately after emulsiﬁcation, the sample was cryogeni-
cally frozen and lyophilised using a Virtis benchtop K
freeze-drier for 48 h. The white dry porous product
was stored at ambient temperature prior to analysis.
Preparation of emulsion-templated freeze-dried
monoliths containing 69% efavirenz labelled with 1%
of the dye 1,10-dioctadecyl-3,3,30,30-
tetramethylindodicarbocyanine, 4-
chlorobenzenesulfonate salt
Preparation followed the same procedure as described
earlier; however, a sock solution of 70 mg/mL 1,10-
dioctadecyl-3,3,30,30-tetramethylindodicarbocyanine,
4-chlorobenzenesulfonate salt (DiD) was prepared in
CHCl3. The four stock solutions were added to a sample
tube in the ratio 97:3: 90:45 (μL) (EFV:DiD:PVA:TPGS)
plus 265 μL water. The ﬁnal solid mass ratio was there-
fore 69% EFV: 1% DiD: 20% PVA: 10% TPGS (total solid
mass 10 mg) in a 1:4 CHCl3 to water mixture (total vol-
ume 0.5 mL). The blue dry porous product was stored at
ambient temperature prior to analysis.
Preparation of emulsion-spray-dried powders con-
taining 70% efavirenz
Stock solutions of EFV (280 mg/mL in DCM), PVA (50 mg/
mL in water), and TPGS (50 mg/mL in water) were
prepared. The three stock solutions were added to a
sample tube in the ratio 16:25.6:12.8 (mL) (EFV:PVA:
TPGS). The ﬁnal solid mass ratio was therefore 70%
EFV, 20% PVA: 10% TPGS (total solid mass 6.4 g) in a
1:2.4 DCM to water mixture (total volume 54.4 mL).
The sample was emulsiﬁed using a Hielscher UP400S ul-
trasonic processor equipped with H7 Probe at 70% out-
put (50 W) for 90 sec. Immediately after
emulsiﬁcation, the sample was spray dried on a bench-
top spray dryer (BUCHI Mini-290) using an air-atomising
nozzle and compressed air as the drying gas. Spray dry-
ing process conditions were 5 mL/min solution ﬂow rate
and 65°C outlet temperature. The white powder was
collected and stored at room temperature before
analysis.
Characterisation of aqueous efavirenz
nanodispersions
Dynamic light scattering
Immediately prior to analysis, samples were dispersed
by addition of water (1 mg/mL with respect to EFV con-
tent, therefore 7 mL for every 10 mg total solid mass)
and vortex mixed to generate a uniform dispersion. Z-
average diameter (Dz), zeta potential (ζ), polydisper-
sity index (PDI), and number average diameter (Dn)
were determined by dynamic light scattering (DLS) at
a temperature of 25°C using a Malvern Zetasizer Nano
ZS equipped with a 4 mW He–Ne, 633 nm laser, and
using plastic disposable cuvettes. Malvern Zetasizer
software version 7.03 was used for data analysis. ζmea-
surements were also carried out at 1 mg/mL, 25°C, and
an initial pH of 6.5, using disposable capillary zeta
cells. Dz , ζ, PDI, and Dn measurements were obtained
as an average of three individual measurements and
were obtained using the instrument’s automatic opti-
misation settings.
Scanning electron microscopy
Scanning electron microscopy (SEM) images were re-
corded using a Hitachi S-4800 ﬁeld emission instrument
(SEM) at 3 kV. Dry samples were placed onto aluminium
stub with carbon tabs. The samples were gold coated
for 2 min at 15 mA using a sputter-coater (EMITECH
K550X) prior to imaging.
Routine human cerebral microvessel
endothelial cells/D3 culture
Human cerebral microvessel endothelial cells/D3 were
cultured in EBM-2 media supplemented with fetal
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bovine serum gold 5%, penicillin-streptomycin 1%, hy-
drocortisone 1.4 μM, ascorbic acid 5 μg/mL, chemically
deﬁned lipid concentrate 1/100, HEPES 10 mM, and
bFGF 1 ng/mL. All culture ﬂasks and plates were coated
with rat collagen type 1 for 1 h prior to use. Cells were
cultured at 37°C in 5% CO2. Cells were passaged every
3–4 days when conﬂuent.
3-(4,5-Dimethylthiazol-2-yl)-2,5-
Diphenyltetrazolium bromide cytotoxicity assay
Cells were seeded on plates pre-coated with collagen at
100 μL of 1 × 105 cells/mL. The plates were then incu-
bated for 24 h at 37°C in 5% CO2 to allow cell adher-
ence. Following incubation, the media was replaced
with 100 μL of fresh media containing the drug at de-
sired concentration (plus vehicle, 0.5% dimethyl sulfox-
ide). Positive and negative controls were represented
by no cells (representing 100% cell death) and by cells
cultured in the presence of a vehicle control
(representing 100% cell viability), respectively. The
cells were then incubated for 1 h. Following incubation
with the drug, the media was removed and replaced by
20 μL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltet-
razolium bromide (MTT) reagent (5 mg/mL solution in
Hanks balanced salt solution (HBSS)). The cells were in-
cubated for 2 h in the MTT reagent. Following incuba-
tion, 100 μL of lysis buffer (50% N-N-
dimethylformamide in water containing 20% sodium do-
decyl sulphate, 2.5% glacial acetic acid and 2.5% HCl,
pH 4.7) was added to each well. Cells were incubated
overnight at 37°C in 5% CO2 to allow complete cell lysis.
Following incubation, the absorbance of each well was
read using the TECAN GENios plate reader, with ﬁlters
set to 560 nm.
Impact of inhibition of drug transporters on
efavirenz cellular accumulation
Cells were seeded on pre-collagenated six-well plates
at a density of 2 × 106/mL and allowed to adhere over-
night. Media was aspirated and replaced with 1 mL
fresh media containing 10 μM (0.014 μCi) of an aque-
ous solution of EFV or EFV SDNs (in the presence or ab-
sence of transporter inhibitors shown in Table 1)
(Dickens et al., 2012). Cells were incubated at 37°C
in 5% CO2 in the presence of the drugs for 1 h. Follow-
ing incubation, 100 μL of media was aspirated and
added to scint vials with 4 mL goldstar scintillation
ﬂuid (extra cellular drug content). Cells were then
washed with ice-cold HBSS ×3. Following washes,
1 mL of trypsin was added to the cells then incubated
at 37°C in 5% CO2 for 15 min. The trypsin was then as-
pirated and added to scint vials with 4 mL goldstar
scintillation ﬂuid (intracellular content). Cellular accu-
mulation ratios (CAR) were calculated using the
following formula (where DPM = disintegrations per
minute):
CAR ¼
intracellular DPM=total cell columeð Þ
extracellular DPM=extracellular volumeð Þ
Cellular volumes were determined using the
ScepterTM cell counter 2.0 (Merck Millipore, Billerica,
USA). Cell volumes were taken from a mean of three
replicates, hCMEC/D3 volume 2.27pl.
Table 1. Inhibitors of transporters or endocytosis that were employed in the study. Also shown are the mechanisms known to be inhibited
with references.
Class Inhibitor Mechanism Reference
Transporter
inhibition
Amantadine OCT1 and OCT2 (Dickens et al., 2012)
Cyclosporine A P-gp, BCRP (Gupta et al., 2006,
Dorababu et al., 2009)
Naringin OATP1A2 (Alﬁrevic et al., 2015)
Corticosterone OCT3 (Dickens et al., 2012)
Endocytosis
inhibition
Dynasore Clathrin-dependent endocytosis (Kirchhausen et al., 2008,
Barrias et al., 2010)
Indomethacin Calveoli-dependent endocytosis (Yumoto et al., 2006)
Cytochalasin B Actin-dependent mechanisms (including
macropinocytosis and phagocytosis)
(MacLean-Fletcher and
Pollard, 1980; Kee et al.,
2004)
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Impact of endocytosis inhibition on efavirenz
accumulation
Cells were seeded on pre-collagenated six-well plates
at a density of 2 × 106/mL and allowed to adhere over-
night. Media was aspirated and replaced with 1 mL
fresh media containing dynasore (100 μM), indometha-
cin (100 μM), or cytochalasin B (5 μM) and incubated
for 30 min at 37°C, 5% CO2 (Table 1) (Kee et al., 2004;
Sato et al., 2009). Following incubation, the media
was aspirated and replaced with fresh media containing
10 μM of EFV aqueous solution formulation EFV or EFV
SDNs. Cells were incubated at 37°C in 5% CO2 in the
presence of the drugs for 1 h. Following 1 h incubation,
1 mL of media was aspirated and added to 1.5 mL
eppendorf tubes (extra cellular content). Cells were
then washed with ice-cold HBSS ×3. Following washes,
1 mL of trypsin was added to the cells then incubated
at 37°C in 5% CO2 for 15 min. The trypsin was then aspi-
rated and added to 1.5 mL eppendorf tubes (intracellu-
lar content). Samples were stored at 80°C until
analysis via Liquid Chromatography Mass Spectrometry
(LC-MS/MS).
CAR ¼
intracellular concentrationð Þ
extracellular concentrationð Þ
Cellular volumes were determined using the
ScepterTM cell counter 2.0 (Merck Millipore, Billerica,
USA). Cell volumes were taken from a mean of three
replicates, hCMEC/D3 volume 2.27pl.
Sample treatment and quantiﬁcation of
efavirenz via LC-MS/MS
Efavirenz was extracted by protein precipitation. A to-
tal of 20 μL of internal standard (lopinavir 1000 ng/mL)
was added to 100 μL of sample (20% acetonitrile (ACN)
was added to cell culture medium to aid EFV dissolu-
tion), standard or QC, which was then treated with
400 μL of ACN. Samples were then centrifuged at
4000 g for 10 min at 4°C. The supernatant fraction
was transferred to a fresh glass vial and placed in a ro-
tary vacuum centrifuge at 30°C to evaporate. Samples
were then and reconstituted in 140 μL of H2O:ACN
(60:40). A total of 100 μL of the sample was then trans-
ferred into 200 μL chromatography vials; 5 μL of each
sample was injected for analysis.
Quantiﬁcation was achieved via LC-MS/MS (TSQ
Endura, Thermo Scientiﬁc) operating in negative mode
(Curley et al., 2016). The following ions were moni-
tored for quantiﬁcation in selected reaction monitoring
scan: EFV (m/z 315 > 242.1, 244.0 and 250.0) and in-
ternal standard, lopinavir (m/z 627 > 121.2, 178.1
and 198.1). A stock solution of 1 mg/mL EFV was pre-
pared in methanol and stored at 4°C until use. A stan-
dard curve was prepared in EBM-2 cell culture medium
by serial dilution from 500 to 1.9 ng/mL, and an addi-
tional blank solution was also used.
Chromatographic separation was achieved using a
multistep gradient with a Hypersil gold C-18 column
(Thermo scientiﬁc) using mobile phases A (100% H2O,
5 mM NH4HCO2) and B (100% ACN, 5 mM NH4HCO2).
Chromatography was conducted over 8.55 min at a ﬂow
rate of 300 μL/min. At the start of each run, mobile
phase A was 90% until 0.1 min when mobile phase B
was increased to 86% at 0.5 min. Mobile phase B was
then gradually increased to 92% over 4.5 min. Mobile
phase B was then increased to 97% at 5.1 min, which
was held until 6 min. Mobile phase A was then increased
to 90% and held till the termination of the run at 8 min.
Inter-assay and intra-assay variance in accuracy and
precision were <15%.
Assessing efavirenz solid drug nanoparticle
uptake by ﬂow cytometry
Cells were seeded on pre-collagenated six-well plates
at a density of 2 × 106/mL and allowed to adhere over-
night. Media was aspirated and replaced with 1 mL
fresh media containing dynasore (100 μM), indometha-
cin (100 μM), or cytochalasin B (5 μM) and incubated
for 30 min. Following incubation, media was aspirated
and replaced with fresh media containing 10 μM of
EFV SDNs containing 1% DiD or control (SDN DiD parti-
cles dissolved in 50% H2O and 50% MeOH) (Liptrott
et al., 2015). Cells were incubated at 37°C in 5% CO2
in the presence of the drugs for 1 h. Following 1 h incu-
bation, media was aspirated and cells were then
washed with ice-cold HBSS ×3. Following washes, 1 mL
of trypsin was added to the cells, then incubated at
37°C in 5% CO2 for 5 min. The cells were then aspirated
and transferred to 1.5 mL eppendorf tubes. Samples
were then centrifuged at 2000 rpm for 5 min at 10°C.
The trypsin was aspirated, and the cell pellet was re-
suspended in 500 μL of Macs buffer for analysis by ﬂow
cytometry using a MACSQuant analyser. Side scatter
outcome was set to logarithmic and detected at a scat-
tering angle of 90°. Flow rates were chosen such that
less than 2000 events/s were recorded to prevent coin-
cidence. For each measurement, a total number of
10,000 events were recorded (Liptrott et al., 2015).
Data were analysed using MACSQuantify software.
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Statistical analysis
All data were assessed for normality using the
Shapiro–Wilk test. Statistical analysis was performed
by unpaired t-test (for normally distributed data) or
Mann–Whitney U test (for non-normally distributed
data), and signiﬁcance was deﬁned as P < 0.05 (cal-
culated in SPSS v21). All data are given as mean with
standard deviation. IC50 values were calculated in
Prism v6.0.
Results
Production and physical characterisation of
efavirenz solid drug nanoparticles
The production of EFV SDNs was conducted using two
emulsion-based techniques, ETFD and emulsion spray
drying (ESD) (Fig. 1). Emulsion-templated freeze-drying
utilises the rapid cryogenic freezing of an oil-in-water
emulsion containing a volatile water-immiscible solvent
dispersed phase containing dissolved hydrophobic com-
pounds (Fig. 1A). The emulsion is stabilised by the pres-
ence of water-soluble polymers and surfactants within
the continuous aqueous phase. Freeze-drying of the
frozen emulsion leads to a porous monolithic structure,
which readily disperses to yield stabilised nanoparticles
of the hydrophobic compounds on addition of water
(Zhang et al., 2008). The incorporation of two hydro-
phobic compounds within the dispersed organic phase
leads to multi-component nanoparticles, and the inclu-
sion of the ﬂuorescer DiD to form EFV/DiD SDNs has
been recently reported using ETFD (Giardiello et al.,
2012; Liptrott et al., 2015). Dispersed dual-component
EFV/DiD nanoparticles were analysed by DLS and shown
to have an average hydrodynamic diameter
(Dz) = 295 ± 25 nm with a PDI = 0.37. Zeta potential
measurements (ζ = 18 ± 0.5 mV) were consistent with
earlier reports.
Efavirenz SDNs were also formed using ESD, which
rapidly dries the emulsion, containing EFV dissolved
within the dispersed organic solvent phase, after
atomisation into a stream of hot air (Fig. 1B). The spray
dryer employed for this study utilised a two-ﬂuid nozzle
and generated spherical powder particles with sizes
ranging from <1 to 10 μm, as judged by SEM imaging
(Fig. 2).
The spray-dried powder particles showed a dimpled
crust morphology (Fig. 2A and B) that is consistent with
the external surface of the atomised droplets of emul-
sion drying quickly within the gas stream, followed by
removal of residual volatile material (water and
organic solvent) in subsequent stages (Fig. 1B). In con-
trast, SEM analysis of ETFD monoliths showed a convo-
luted open morphology (Fig. 2C and D) with little
evidence of ice crystal growth or removal that may be
seen in materials that have been freeze dried directly
from aqueous solutions (Zhang et al., 2005). Dispersion
of ESD powders into water resulted in nanodispersions
that were also studied by DLS and found to have similar
values to the ETFD SDNs containing 1 wt% DiD a Dz value
of 250 ± 25 nm, PDI = 0.26, and ζ = 10 ± 0.1 mV.
The conformity of size and physical properties across
the ETFD and ESD techniques suggested no inherent or
meaningful difference (within error) between the two
samples other than the presence of DiD. The use of
the two techniques was required to allow correlation
of the readily traceable EFV/DiD nanoparticles, pro-
duced by ETFD due to the prohibitive cost of DiD, with
an ESD EFV nanoformulation that is progressing towards
human clinical trial. Imaging of the SDN single and dual-
component particles after dispersion is signiﬁcantly
hampered by the presence of water-soluble polymer
and surfactant excipients as reported previously (Zhang
et al., 2008).
Cytotoxicity of efavirenz solution, efavirenz
solid drug nanoparticles, and inhibitors in
human cerebral microvessel endothelial
cells/D3 cells
Prior to accumulation studies, it was necessary to de-
termine the concentrations of EFV in solution, EFV
SDNs, and the various inhibitors that did not affect cell
viability. To assess the cellular toxicity of the com-
pounds used in accumulation studies, a concentration
range of each drug was assessed using the MTT assay.
Table 1 summarises the IC50 data for all drugs and for-
mulations used in the study. Efavirenz solution and EFV
SDNs were assessed over the range of 0.19 μM to 100 μM
EFV concentration. No statistically signiﬁcant differ-
ence was observed in IC50 between the aqueous solu-
tion and the SDN (P = 0.49).
Transporter inhibitors were assessed over the ﬁnal
concentration range of 0.98 μM to 500 μM. The IC50
could not be generated for amantadine, cyclosporine
A, naringin, or corticosterone as cytotoxicity was not
observed under these conditions. Endocytosis inhibitors
were assessed over the range of 0.39 to 200 μM. Simi-
larly, the IC50 could not be generated for dynasore and
indomethacin, as cytotoxicity was not observed under
the experimental conditions.
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Impact of drug transporter inhibition on
efavirenz accumulation
Cellular accumulation studies were performed in the
hCMEC/D3 cell line, and a panel of transporter inhibi-
tors (Table 2) was employed to probe potential
interactions with an EFV aqueous solution with trans-
porters. Secondly, the accumulation of EFV SDNs in
the presence of transporter inhibitors was probed to
identify any differences in cellular accumulation due
to nanoformulation (Fig. 3).
Figure 1. Schematic illustration of solid drug nanoparticle formation techniques. (A) Emulsion-templated freeze drying involves the fol-
lowing: (i) the dissolution of poorly soluble drug compound into a water-immiscible solvent and the dissolution of water-soluble excipients
into water; (ii) emulsiﬁcation; (iii) freezing and freeze-drying to yield a dry, porous monolith; and (iv) redispersion into water. (B) Emul-
sion spray drying involves the following: (i) the ﬂow of the emulsion containing poorly soluble drug in the dispersed volatile organic phase
and water-soluble excipients within the continuous phase through an atomiser, to form (ii) droplets of emulsion that rapidly dry in the hot
air ﬂow, initially forming (iii) a solidiﬁed crust with increased concentrations within the remaining liquid phase, and latterly, (iv) dry pow-
der particles comprising solid drug nanoparticles within a dry excipient mixture.
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The screen of transporter inhibitors demonstrated no
effect on the accumulation ratio of the EFV aqueous so-
lution when in the presence of cyclosporine A
(CAR = 70.3 ± 27.7, P = 0.51), naringin (CAR = 89.6 ± 8.1,
P = 0.18), or corticosterone (CAR = 80.8 ± 12.5,
P = 0.96). However, the accumulation ratio was reduced
in the presence of amantadine (CAR 64.7 ± 6.0,
P = 0.03).
The accumulation ratio of EFV after incubation with
the SDN formulation was not affected by amantadine
(CAR = 91. 9 ± 22.7, P = 0.40), cyclosporine A
(CAR = 73.1 ± 17.2, P = 0.40), naringin (CAR = 89.1 ± 15.7,
P = 0.38), or corticosterone (CAR = 77.2 ± 12.2,
P = 0.57).
The effects of inhibitors of endocytosis on
efavirenz accumulation
In addition to transport proteins, endocytosis is a po-
tential mechanism for cellular uptake, especially for
particulates. To probe the impact of endocytosis on
the uptake of EFV aqueous solution and EFV SDNs, a
Table 2. Cytotoxicity of all drugs and formulations used in the study in cerebral microvessel endothelial cells/D3 cells. IC50 values rep-
resent mean ± standard deviation.
Class Drug IC50 (μM, mean ± SD)
Aqueous solution (<1% DMSO) Efavirenz 66.8 (21.32)
SDN aqueous dispersion Efavirenz 57.6 (5.98)
Transport inhibitor Amantadine >500
Cyclosporine A >500
Naringin >500
Corticosterone >500
Endocytosis inhibitor Dynasore >200
Indomethacin >200
Cytochalasin B 3.3 (2.88)
DMSO, dimethyl sulfoxide; SD, standard deviation; SDN, solid drug nanoparticle.
Figure 2. Scanning electron microscopy images of solid drug nanoparticle containing powders and monoliths: A&B) Emulsion spray dried
powder particles, and C&D) internal morphology of emulsion template freeze dried monoliths. All images are structures prior to re-disper-
sion into water and release of solid drug nanoparticles.
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panel of endocytosis inhibitors was screened (Table 1)
and the resulting data are presented in Figure 4.
The screen of endocytosis inhibitors demonstrated
no effect on the accumulation ratio of either the aque-
ous solution (CAR = 92.7 ± 47.4) or SDNs
(CAR = 118.7 ± 41.0) when in the presence of dynasore
(aqueous CAR = 96.7 ± 13.1, P = 0.87, SDN
CAR = 121.8 ± 18.0, P = 0.90), indomethacin (aqueous
CAR = 137.6 ± 60.0, P = 0.29, SDN CAR = 119.4 ± 16.5,
P = 0.98), or cytochalasin B (aqueous CAR = 96.5 ± 47.2,
P = 0.91, SDN CAR = 141.4 ± 35.4, P = 0.43).
The effects of inhibitors of endocytosis on
nanoparticle uptake using ﬂow cytometry
The uptake of DiD-labelled EFV SDNs (4.02 ± 0.86 rela-
tive ﬂuorescence units (RFU)) was signiﬁcantly reduced
(Fig. 5) by dynasore (0.91 ± 0.45 RFU, P = 0.001). Indo-
methacin had no effect on uptake of DiD-labelled EFV
SDNs (3.44 ± 0.58 RFU, P = 0.307), whereas cytochalasin
B signiﬁcantly increased uptake (5.40 ± 0.70 RFU,
P = 0.048; Fig. 6).
The uptake of dissolved DiD-labelled EFV-SDNs
(8.75 ± 1.14 RFU) was signiﬁcantly reduced by dynasore
A B
Figure 3. Shown are the cellular accumulation ratios generated for efavirenz (EFV) (A) and solid drug nanoparticle (SDN) efavirenz (B).
Also shown are the cellular accumulation ratios in the presence of amantadine, cyclosporine A, naringin, and corticosterone. Data points
indicate mean (±SD).
Figure 4. Shown are the cellular accumulation ratios generated for efavirenz (EFV) (A) and solid drug nanoparticle (SDN) EFV (B). Also
shown are the cellular accumulation ratio in the presence of dynasore, indomethacin, and cytochalasin B. Data points indicate mean
(±SD).
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Figure 5. Scatter plot of the ﬂuorescence detected at 655–730 nm. The green plot represents untreated cells (A–D). The red plot repre-
sents cells treated with DiD-labelled SDN (A–D). The blue plot represents the ﬂuorescence in the presence of dynasore (B), indomethacin
(C), and cytochalasin B (D).
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Figure 6. Shown is the ﬂuorescence produced by cells treated with solid drug nanoparticle (SDN) 1,10-dioctadecyl-3,3,30,30-
tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate salt (DiD) efavirenz (A) and dissolved SDN DiD efavirenz (B) in the presence
of dynasore, indomethacin, and cytochalasin B. Data points indicate mean (±SD).
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(0.43 ± 0.13 RFU, P = <0.001) and indomethacin
(4.45 ± 0.54 RFU, P = <0.001). Cytochalasin B signiﬁ-
cantly increased the uptake of dissolved DiD-labelled
EFV SDNs (12.12 ± 0.20 RFU, P = <0.001; Fig. 6).
Discussion
The data presented here demonstrated that cellular ac-
cumulation of aqueous EFV was reduced by amantadine
(19.5% vs. control), but this was not the case when in-
cubating with EFV SDNs. These data indicate that aque-
ous EFV may be a substrate for one of the OCT
transporters and the SDN formulation may mitigate
the inﬂuence of these transporters. Further transport
studies are required to fully conﬁrm these observations
using multiple time points and a range of concentra-
tions of substrate and inhibitor. The SDN formulation
procedure generates particles with sizes of
322 ± 29 nm. Particles of this size are subjected to en-
docytosis, and nanoformulation has been used previ-
ously to reduce the impact of the transporter, BCRP
(Canton and Battaglia, 2012; Wong et al., 2006). Fur-
ther studies are required to fully elucidate the interac-
tions of both the EFV aqueous solution and SDN
formulations.
The data generated utilising the endocytosis inhibi-
tors provided some contrasting data. When the drug ac-
cumulation ratio was examined, the endocytosis
inhibitors had no effect on either the aqueous solution
or the SDN formulation of EFV. Interestingly, uptake of
the DiD-labelled SDNs was reduced by dynasore, indi-
cating the role of dynamin-mediated uptake. However,
the uptake of the dissolved DiD-labelled SDNs was re-
duced by both dynasore and indomethacin. This may in-
dicate the incomplete dissolution of the SDN particles
or that the dissolution process has altered the structure
of the SDN particles, enabling uptake via calveoli-
dependent endocytosis. The data also demonstrated
higher uptake for the dissolved DiD SDN particles. This
is not entirely unexpected, as DiD is a lypophilic dye
and would be expected to readily pass through the lipid
cell wall. This limitation could be resolved by the use of
a cell impermeable dye, such as propidium iodide (ﬂuo-
rescence only observed when associated with intracel-
lular nucleic acids). Propidium iodide has previously
been incorporated into rhodamine B isothiocyanate–
labelled silica nanoparticles to indicate cellular uptake
(Neumeyer et al., 2011). These data indicate the im-
portance of measuring both nanoparticle uptake and
drug uptake. Although the drug concentrations may be
equal in both preparations, the mechanism of cell entry
and consequently intracellular fate may be signiﬁcantly
different.
The hCMEC/D3 cell line has been demonstrated to
express many of the proteins found in the enterocytes
of the BBB, making this cell line a suitable model for
probing interactions at the BBB (Weksler et al., 2013).
One of the limitations of the hCMEC/D3 cell line is the
formation of tight junctions (Stanimirovic et al.,
2015). The BBB is characterised by the presence of tight
junctions, limiting paracellular transport. To fully repli-
cate the presence of tight junctions, the hCMEC/D3 cell
line requires technically demanding and prohibitively
expensive culture conditions. It has been demonstrated
to reproduce the tight junctions observed in vivo, but
sheer stress induced by a pulsatile ﬂow was required
(Cucullo et al., 2008). Although accumulation experi-
ments are useful for identifying potential mechanisms
of uptake at the BBB, they do not demonstrate perme-
ability across the BBB.
One of the limitations of investigating transporter in-
teractions in cell lines is the lack of speciﬁcity in phar-
macological transport inhibitors. Lack of speciﬁcity is
also a consideration when examining inhibitors of endo-
cytosis (Ivanov, 2008). In addition to other mechanisms
of endocytosis, endocytosis inhibitors have also been
shown to inﬂuence transport proteins, such as inhibition
of ABCC1 by indomethacin (Leite et al., 2007). Cytocha-
lasin B was shown to disrupt actin ﬁlaments and increase
the intracellular accumulation of doxorubicin. There-
fore, the conclusions that are drawn here are based on
the known interactions of the inhibitors used but inhibi-
tion of other, as yet unknown processes cannot be ruled
out with this strategy. Further studies utilising more
speciﬁc methods (such as knock-down models, small in-
terfering RNA, and oocyte uptake experiments) may be
useful to complement in vivo studies and further
elucidate the interactions relevant to distribution.
An additional limitation of the experimental design
was that all experiments were conducted at 1 h. How-
ever, Liptrott et al. (2012) previously demonstrated
that the CAR of EFV SDNs varied over 24 h in THP-1
cells, with the highest accumulation achieved within
the ﬁrst hour.
The presented data indicate that EFV SDNs may not
traverse the BBB via the same mechanisms as dissolved
EFV molecules. Amantadine signiﬁcantly reduced EFV
uptake, while there was no effect observed with the
SDNs. In addition, dynasore reduced the uptake of
DiD-labelled SDN particles indicating a role of
dynamin-mediated endocytosis.
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